Laurence De Moerlooze
YOU?
Author Swipe
View article: A multivalent RSV vaccine based on the Modified Vaccinia Ankara vector shows moderate protection against disease caused by RSV in older adults in a Phase 3 clinical study
A multivalent RSV vaccine based on the Modified Vaccinia Ankara vector shows moderate protection against disease caused by RSV in older adults in a Phase 3 clinical study Open
Respiratory syncytial virus (RSV) causes a significant disease burden in older adults. The live recombinant vaccine based on a nonreplicating modified vaccinia Ankara (MVA-BN) poxvirus, MVA-BN-RSV, encoding for multiple proteins of RSV sub…
View article: Reduced Respiratory Syncytial Virus Load, Symptoms, and Infections: A Human Challenge Trial of MVA-BN-RSV Vaccine
Reduced Respiratory Syncytial Virus Load, Symptoms, and Infections: A Human Challenge Trial of MVA-BN-RSV Vaccine Open
Background Respiratory syncytial virus (RSV) causes significant disease burden in older adults. MVA-BN-RSV is a novel poxvirus-vectored vaccine encoding internal and external RSV proteins. Methods In a phase 2a randomized double-blind, pla…
View article: The Quest for a Respiratory Syncytial Virus Vaccine for Older Adults: Thinking beyond the F Protein
The Quest for a Respiratory Syncytial Virus Vaccine for Older Adults: Thinking beyond the F Protein Open
Respiratory syncytial virus (RSV) is a common cause of paediatric respiratory tract infection and causes a significant health burden in older adults. Natural immunity to RSV is incomplete, permitting recurrent symptomatic infection over an…
View article: Decreased Viral Load, Symptom Reduction, and Prevention of Respiratory Syncytial Virus Infection with MVA-BN-RSV Vaccine
Decreased Viral Load, Symptom Reduction, and Prevention of Respiratory Syncytial Virus Infection with MVA-BN-RSV Vaccine Open
Background Respiratory syncytial virus (RSV) causes significant disease burden in infants and older adults. Most vaccines in development focus on the virus’s F protein. MVA-BN-RSV is a novel vectored vaccine encoding internal and external …
View article: One- and Two-Dose Vaccinations With Modified Vaccinia Ankara-Bavarian Nordic Induce Durable B-Cell Memory Responses Comparable to Replicating Smallpox Vaccines
One- and Two-Dose Vaccinations With Modified Vaccinia Ankara-Bavarian Nordic Induce Durable B-Cell Memory Responses Comparable to Replicating Smallpox Vaccines Open
Background Although modified vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccination is approved for smallpox and monkeypox prevention, immunological persistence and booster effects remain undescribed. Methods Participants naive to smallpox v…
View article: Single and 2-dose vaccinations with MVA-BN<sup>®</sup> induce durable B cell memory responses in healthy volunteers that are comparable to older generation replicating smallpox vaccines
Single and 2-dose vaccinations with MVA-BN<sup>®</sup> induce durable B cell memory responses in healthy volunteers that are comparable to older generation replicating smallpox vaccines Open
While the MVA-BN vaccine has been proven protective against smallpox and monkeypox, the long-term immunological persistence or booster effect has not been described. In this set of clinical studies, participants who had never been immunize…
View article: Perceptions of tick-borne encephalitis risk: a survey of travellers and travel clinics from Canada, Germany, Sweden and the UK
Perceptions of tick-borne encephalitis risk: a survey of travellers and travel clinics from Canada, Germany, Sweden and the UK Open
There is a need to increase awareness of the risk and prevention of TBE among travellers to endemic countries, and travel clinics could play an important role in this process. 5975671594001tay062media15975671594001.
View article: Perceptions of rabies risk: a survey of travellers and travel clinics from Canada, Germany, Sweden and the UK
Perceptions of rabies risk: a survey of travellers and travel clinics from Canada, Germany, Sweden and the UK Open
These findings suggest that although travellers had frequently heard of rabies, awareness of the risks of this serious infectious disease was relatively low. 5975671594001tay062media15975671594001.
View article: German travelers’ preferences for travel vaccines assessed by a discrete choice experiment
German travelers’ preferences for travel vaccines assessed by a discrete choice experiment Open
The travelers' responses indicated strong preferences for selecting vaccination rather than opting out of vaccination, and disease risk, health impact and vaccine cost were the most important features for vaccine choice.
View article: Incidence and prevalence of hepatitis B in patients with diabetes mellitus in the <scp>UK</scp>: A population‐based cohort study using the <scp>UK</scp> Clinical Practice Research Datalink
Incidence and prevalence of hepatitis B in patients with diabetes mellitus in the <span>UK</span>: A population‐based cohort study using the <span>UK</span> Clinical Practice Research Datalink Open
Summary We assessed the incidence and prevalence of hepatitis B (Hep B) in patients with or without diabetes mellitus (DM) using the UK Clinical Practice Research Datalink (CPRD). This was a retrospective, observational study of diabetic a…
View article: Systematic literature review comparing rapid 3-dose administration of the GSK tick-borne encephalitis vaccine with other primary immunization schedules
Systematic literature review comparing rapid 3-dose administration of the GSK tick-borne encephalitis vaccine with other primary immunization schedules Open
Tick-borne encephalitis (TBE), which is endemic across large regions of Europe and Asia, is most effectively prevented through vaccination. Three-dose primary TBE vaccination schedules are either rapid (0,7,21-days) or conventional (0,28-8…
View article: Should adults with diabetes mellitus be vaccinated against hepatitis B virus? A systematic review of diabetes mellitus and the progression of hepatitis B disease
Should adults with diabetes mellitus be vaccinated against hepatitis B virus? A systematic review of diabetes mellitus and the progression of hepatitis B disease Open
Despite the burden of diabetes mellitus (DM), little is known about the role of this and other metabolic syndromes on the severity of hepatitis B virus (HBV) chronicity and liver disease progression. The value of hepatitis B vaccination an…
View article: The immunogenicity of GSK’s recombinant hepatitis B vaccine in children: a systematic review of 30 years of experience
The immunogenicity of GSK’s recombinant hepatitis B vaccine in children: a systematic review of 30 years of experience Open
The World Health Organization recommends hepatitis B virus (HBV) vaccines to be included in national immunization schedules everywhere, and has adopted the strategic goal of halting viral hepatitis as a major public health threat by 2030, …
View article: The immunogenicity and safety of GSK’s recombinant hepatitis B vaccine in adults: a systematic review of 30 years of experience
The immunogenicity and safety of GSK’s recombinant hepatitis B vaccine in adults: a systematic review of 30 years of experience Open
Engerix B (GSK HepB, GSK, Belgium) was the first recombinant hepatitis B virus vaccine to be licensed, and marked its 30th anniversary in 2016. Vaccination of adult populations against HBV is usually implemented on a risk-based approach wi…
View article: Impact of universal mass vaccination with monovalent inactivated hepatitis A vaccines – A systematic review
Impact of universal mass vaccination with monovalent inactivated hepatitis A vaccines – A systematic review Open
The WHO recommends integration of universal mass vaccination (UMV) against hepatitis A virus (HAV) in national immunization schedules for children aged ≥1 year, if justified on the basis of acute HAV incidence, declining endemicity from hi…
View article: Pre-travel advice, attitudes and hepatitis A and B vaccination rates among travellers from seven countries<sup>†</sup>
Pre-travel advice, attitudes and hepatitis A and B vaccination rates among travellers from seven countries<sup>†</sup> Open
Background: Knowledge about the travel-associated risks of hepatitis A\nand B, and the extent of pre-travel health-advice being sought may vary between\ncountries.
View article: HAV & HBV vaccination among travellers participating in the National Health and Wellness Survey in five European countries
HAV & HBV vaccination among travellers participating in the National Health and Wellness Survey in five European countries Open
Travel frequency and destination endemicity are associated with increased hepatitis A and B vaccination. The number of unvaccinated travellers and the lack of recall for the dosing schedule suggest the need to improve travellers' awareness…
View article: Immunogenicity, effectiveness and safety of combined hepatitis A and B vaccine: a systematic literature review
Immunogenicity, effectiveness and safety of combined hepatitis A and B vaccine: a systematic literature review Open
The vaccine offers satisfactory long-term immunogenicity rates, expected duration of protection and safety profile similar to the monovalent hepatitis A or B vaccines.